

March 1, 2017



Aethlon Medical Announces the Grant of a European Patent Protecting Methods of Quantifying Exosomes

SAN DIEGO, March 1, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that the European Patent Office has granted European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES."

In recent years, exosomes have emerged as a significant diagnostic and therapeutic targets for a wide range of disease conditions, including cancer, infectious viruses, tuberculosis, Alzheimer's, and chronic traumatic encephalopathy (CTE). This granted European Patent is an important addition to Aethlon Medical's patent portfolio as it protects methods for quantifying any type of exosome captured by lectin affinity using Galanthus nivalis lectin (GNA), Narcissus pseudonarcissuslectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL) or concanavalin A. The patent has claims encompassing methods of quantifying exosomes associated with CTE, Alzheimer's, cancer, or any other disease condition by contacting a sample having any type of exosome with GNA, NPA, ASA, LCH, SNA, MAL, or concanavalin A immobilized on a substrate, contacting the bound exosomes with a detectable exosome-binding agent, and measuring a signal from the bound detectable exosome-binding agent, thereby quantifying the bound exosomes. This European patent further expands Aethlon Medical's established patent position on diagnostic and therapeutic approaches in the field of exosome biology.

About Aethlon Medical

Aethlon Medical develops immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® reduces the presence of circulating viruses in infected individuals. The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism. The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens. At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study. Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.

Aethlon Medical is also the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). ESI's TauSome™ biomarker is being clinically evaluated as the basis for a blood-based test to identify CTE in living individuals. Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com. You can

also connect with us on Twitter, LinkedIn, Facebook and Google+.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, including clearance through the 21st Century Cures Act, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2016, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:

Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-489-7800 extension 3300
Jfrakes@aethlonmedical.com

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/aethlon-medical-announces-the-grant-of-a-european-patent-protecting-methods-of-quantifying-exosomes-300415679.html>

SOURCE Aethlon Medical, Inc.